Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06721247
Active, not recruiting Phase 2/3

Oral Intake of Mg in Controlled Asthmatic Patients

NCT06721247 · tracked via the Priya Life Science Egypt tracker
Sponsor
Zagazig University
Phase
Phase 2/3
Started
2024-11-02
Last updated
2025-08-14

Condition(s) studied

Bronchial Asthma

Investigational drug(s) / intervention(s)

Magnesium →ICS+LABAAll ICS) trials (2) →All LABA trials (2) →

Magnesium: oral intake of magnesium for asthmatic patients with dose 200 mg per day for one year in addition to usual asthmatic treatment according to GINA guidelines 2024

ICS+LABA: inhaled corticosteroids with long acting Beta 2 agonist are given to control group patients twice daily

Study summary

The goal of this clinical trial is to assess the efficacy of oral magnesium supplements in controlled asthmatic patients for proper effective asthma management to reduce frequency of asthma exacerbation \& to test the effect of oral magnesium supplementation on improvement of both clinical symptoms and lung functions in patients with bronchial asthma.. The main questions it aims to answer are:

• Can oral supplementation of magnesium play a role in decrease the number of bronchial asthma exacerbations , number of ER visits , number of doctor visits and improve lung function ? Researchers will compare patients on usual treatment according to GINA guidelines 2024 group B and those taking oral magnesium together with the usual group A .

Participants will:

* Take oral magnesium treatment with usual asthma medications according to GINA guidelines (2024) every day for 1year
* Visit the clinic once every 2 weeks for checkups and tests
* Keep a diary of their day and night symptoms and the number of times they had activity limitation due to asthma and the number of use reliever.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years. * Stable controlled asthmatic patients . Exclusion Criteria: * Medical conditions and disorders (such as chronic kidney disease, diabetes mellitus, cardiac disease, alcoholism, diarrhea, and pregnancy). * Any treatment which might affect the absorption or excretion of Mg2+ including digoxin, diuretics, and calcium-containing medications. * Patients in asthma exacerbations .

Primary outcome measure(s)

  • improvement in the degree of asthma control — 6 months to one year
    By using GINA assessment of symptom control and future risk including 1) decrease daytime symptoms of asthma. 2) decrease use of relievers . 3)improvement in daily activities. 4) decrease night awakening due to asthma symptoms . By using pulmonary function tests (Spirometer) specially Forced expiratory volume in the first second (FEV1) , any improvement in pulmonary function will be measured .

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine Zagazig University Zagazig Egypt

More Zagazig University trials in Egypt

Correction of Head Turn in Idiopathic Infantile Nystagmus Active, not recruiting
Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata Recruiting
Total Intravenous Anesthesia in Patients Undergoing Craniotomy Active, not recruiting
Outcomes of Using FANS With FURS in TTT of Lower Calyceal Stones. Recruiting
Clinical Performance of Laryseal Clear Versus Ambu Aura 40 Laryngeal Mask Airway for Preschool Children Recruiting

Other trials for the same condition

Echo and Electrocardiographic Findings in Children With Bronchial Asthma At Sohag University Hospital Starting soon
Prevelance of Broncial Asthma and Allergic Rhinitis in Children With Nephrotic Syndrim Starting soon
Behavioral Changes Among Asthmatic Children in Sohag Universty Hospital Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06721247 on ClinicalTrials.gov ↗ ← All trials in Egypt